BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22011448)

  • 1. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
    Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
    J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
    Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
    J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora kinases as prognostic biomarkers in ovarian carcinoma.
    Mendiola M; Barriuso J; Mariño-Enríquez A; Redondo A; Domínguez-Cáceres A; Hernández-Cortés G; Pérez-Fernández E; Sánchez-Navarro I; Vara JA; Suárez A; Espinosa E; González-Barón M; Palacios J; Hardisson D
    Hum Pathol; 2009 May; 40(5):631-8. PubMed ID: 19157502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FEZ1/LZTS1 protein expression in ovarian cancer.
    Califano D; Pignata S; Pisano C; Greggi S; Laurelli G; Losito NS; Ottaiano A; Gallipoli A; Pasquinelli R; De Simone V; Cirombella R; Fusco A; Chiappetta G
    J Cell Physiol; 2010 Feb; 222(2):382-6. PubMed ID: 19885841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
    Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
    Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy.
    Lassmann S; Shen Y; Jütting U; Wiehle P; Walch A; Gitsch G; Hasenburg A; Werner M
    Clin Cancer Res; 2007 Jul; 13(14):4083-91. PubMed ID: 17634533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
    Lassus H; Staff S; Leminen A; Isola J; Butzow R
    Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
    Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
    Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
    Matsuo K; Bond VK; Im DD; Rosenshein NB
    Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases.
    Classe JM; Jaffre I; Frenel JS; Bordes V; Dejode M; Dravet F; Ferron G; Marchal F; Rigaud DB; Loussouarn D; Campion L
    Eur J Surg Oncol; 2011 Nov; 37(11):971-7. PubMed ID: 21944959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
    Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.